Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI‐0052 (marizomib) in a human plasmacytoma xenograft murine model

Summary Our previous study showed that the novel proteasome inhibitor NPI‐0052 induces apoptosis in multiple myeloma (MM) cells resistant to conventional and bortezomib (Velcade™, Takeda, Boston, MA, USA) therapies. In vivo studies using human MM‐xenografts demonstrated that NPI‐0052 is well tolerat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2010-05, Vol.149 (4), p.550-559
Hauptverfasser:	Singh, Ajita V., Palladino, Michael A., Lloyd, George Kenneth, Potts, Barbara C., Chauhan, Dharminder, Anderson, Kenneth C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use apoptosis Biological and medical sciences Dose-Response Relationship, Drug Drug Evaluation, Preclinical - methods Hematologic and hematopoietic diseases Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Kidney - metabolism Lactones - pharmacokinetics Lactones - pharmacology Lactones - therapeutic use Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Mice multiple myeloma pharmacology Plasmacytoma - drug therapy Plasmacytoma - metabolism Plasmacytoma - pathology Proteasome Inhibitors Pyrroles - pharmacokinetics Pyrroles - pharmacology Pyrroles - therapeutic use Rats Rats, Sprague-Dawley Tumor Cells, Cultured Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!